Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ACHV · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic… NCT01630733 · Non-Small Cell Lung Cancer Custirsen, Docetaxel | ACHV Achieve Life Sciences | Phase 3 | Completed | 664 | Nov 17, 2016 | Registry ↗ |
| Feb 6, 2026 | Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Us… NCT07392125 · Vaping Cessation Cytisinicline, Placebo | ACHV Achieve Life Sciences | Phase 3 | Not yet recruiting | 800 | Nov 15, 2026 | Registry ↗ |
| Jan 15, 2026 | A Study of Cytisinicline for Smoking Cessation in Adult Smokers NCT04576949 · Smoking Cessation Cytisinicline, Placebo | ACHV Achieve Life Sciences | Phase 3 | Completed | 810 | Dec 23, 2021 | Registry ↗ |
| Jan 14, 2026 | A Study of Cytisinicline for Vaping Cessation in Adult Smokers NCT05431387 · Vaping, E-Cig Use cytisinicline, Placebo | ACHV Achieve Life Sciences | Phase 2 | Completed | 160 | Feb 28, 2023 | Registry ↗ |
| Jan 14, 2026 | A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers NCT05206370 · Smoking Cessation Cytisinicline, Placebo | ACHV Achieve Life Sciences | Phase 3 | Completed | 792 | Mar 21, 2023 | Registry ↗ |
| Nov 26, 2025 | Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers NCT06435221 · Smoking Cessation, Vaping Cessation Cytisinicline | ACHV Achieve Life Sciences | Phase 3 | Completed | 479 | Sep 29, 2025 | Registry ↗ |
| Jul 11, 2025 | Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of… NCT05631938 · Renal Impairment cytisinicline | ACHV Achieve Life Sciences | Phase 1 | Completed | 44 | Sep 4, 2023 | Registry ↗ |
| Oct 18, 2023 | Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK)… NCT05981768 · Smoking Cessation Cytisinicline | ACHV Achieve Life Sciences | Phase 1 | Completed | 30 | Sep 21, 2023 | Registry ↗ |
| May 18, 2023 | Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinic… NCT05566288 · Smoking Cessation Cytisinicline, Placebo | ACHV Achieve Life Sciences | Phase 1 | Completed | 27 | Dec 23, 2022 | Registry ↗ |
| Sep 17, 2020 | A Single Dose-escalation Study of Cytisine in Adult Smokers NCT03848208 · Smoking Cessation cytisine, placebo | ACHV Achieve Life Sciences | Phase 1 | Completed | 74 | Sep 12, 2019 | Registry ↗ |
| May 18, 2020 | Trial of Cytisine in Adult Smokers NCT03709823 · Smoking Cessation Cytisine, Placebo Comparator | ACHV Achieve Life Sciences | Phase 2 | Completed | 254 | Apr 23, 2019 | Registry ↗ |
| Oct 21, 2019 | A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers NCT03303911 · Smoking Cessation Cytisine | ACHV Achieve Life Sciences | Phase 1/2 | Terminated | 26 | Oct 5, 2018 | Registry ↗ |
| Sep 24, 2019 | A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in… NCT03509948 · Smoking Cessation cytisine | ACHV Achieve Life Sciences | Phase 1 | Completed | 13 | Jun 10, 2018 | Registry ↗ |
| Feb 26, 2019 | A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine NCT03268343 · Smoking Cessation Cytisine | ACHV Achieve Life Sciences | Phase 1 | Completed | 24 | Aug 26, 2017 | Registry ↗ |
| Oct 14, 2016 | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With… NCT01188187 · Prostate Cancer Custirsen, Docetaxel | ACHV Achieve Life Sciences | Phase 3 | Completed | 1,022 | Feb 2014 | Registry ↗ |
| Oct 12, 2016 | Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemothera… NCT01578655 · Prostate Cancer cabazitaxel, prednisone | ACHV Achieve Life Sciences | Phase 3 | Completed | 630 | Jul 2016 | Registry ↗ |
| Oct 12, 2016 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Caba… NCT01083615 · Castrate-Resistant Prostate Cancer, Hormone Refractory Pros… custirsen sodium, isotonic, 0.9% sodium chloride | ACHV Achieve Life Sciences | Phase 3 | Terminated | 14 | Mar 2013 | Registry ↗ |
| Oct 10, 2016 | Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repola… NCT01874561 · Cardiac Conduction and Repolarization Custirsen, Placebo | ACHV Achieve Life Sciences | Phase 1 | Completed | 155 | Dec 2013 | Registry ↗ |
| Oct 10, 2016 | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood… NCT01497470 · Cancer Custirsen, paclitaxel and carboplatin | ACHV Achieve Life Sciences | Phase 1 | Completed | 36 | Jul 2013 | Registry ↗ |
| Oct 7, 2016 | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Blad… NCT01454089 · Urologic Neoplasms, Metastatic Bladder Cancer OGX-427 600 mg, OGX-427 1000 mg | ACHV Achieve Life Sciences | Phase 2 | Completed | 183 | Nov 2014 | Registry ↗ |
| Jan 18, 2016 | Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer NCT00487786 · Neoplasms OGX-427, Docetaxel | ACHV Achieve Life Sciences | Phase 1 | Completed | 64 | Jun 2011 | Registry ↗ |
21 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances